Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

74.22 -0.34 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
64 65 Next >
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Benzinga 
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last... 
Via Benzinga
AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
AstraZeneca Plc (NASDAQ: AZN) has reported topline data 
Via Benzinga
TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
From AstraZeneca
Via Business Wire
Is AstraZeneca Stock a Buy for Growth Investors?
This drugmaker is among the largest international players in the world. 
Via The Motley Fool
AstraZeneca Unusual Options Activity
Via Benzinga
What Does AstraZeneca's Debt Look Like?
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How To Trade US CPI: The Top 5 Mega-Cap Gainers And Losers Following Last 3 Inflation Reports
Investors are eagerly awaiting the U.S. inflation statistics for April, which will be announced on Wednesday at 8.30 a.m. ET, before the start of trading on Wall Street. 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,700 Today
Via Benzinga
AstraZeneca Plc (AZN) Q1 2023 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Earnings Outlook For AstraZeneca
Via Benzinga
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
From AstraZeneca
Via Business Wire
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
The 7 Best Mutual Funds to Invest in for May 2023
With rising uncertainties in the economy and the capital markets, investors have an incentive to consider the best mutual funds. 
Via InvestorPlace
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
The World Health Organization ended the global emergency 
Via Benzinga
AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Friday Morning
Via Investor Brand Network
A Look Into AstraZeneca's Debt
Via Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%. 
Via Talk Markets
3 Low-Volatility Stocks for a Stable Investment Strategy
These are the low-volatility stocks to buy for high total returns as they represent attractively-valued dividend names. 
Via InvestorPlace
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
Via Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat... 
Via Benzinga
7 Low-Risk Stocks to Buy if You Only Want to Beat Inflation
Getting in on some low-risk stocks is a good idea if you want to preserve your capital during inflation and before the upcoming recession. 
Via InvestorPlace
Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and... 
Via Benzinga
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
From AstraZeneca
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.